Cantor Fitzgerald reiterates Ideaya Biosciences stock rating

Cantor Fitzgerald reiterated its Overweight rating on Ideaya Biosciences, whose shares have risen nearly 50% over the past year to $38.86; its $65 target implies roughly 35% upside. The key catalyst is updated data from about 100 patients in the IDE849 DLL3 ADC program, including initial neuroendocrine carcinoma results and overall-survival data in small-cell lung cancer, alongside Phase 2 darovasertib data in uveal melanoma. Guggenheim raised its target to $57 from $54 and Citizens upgraded IDYA to Market Outperform with a $42 target, though InvestingPro flags the stock as appearing overvalued despite net cash.

Analysis

IDYA’s valuation is now primarily an event-driven underwriting exercise rather than a sell-side-target opportunity. The decisive variable is whether IDE849 demonstrates a therapeutic index and durability sufficient to differentiate in DLL3, where prior enthusiasm has repeatedly been undermined by toxicity, antigen heterogeneity, and the difficulty of translating China-only dose-expansion data to Western populations. A clean survival signal could support a major rerating over 1-3 months; weak duration, discontinuations, or a mismatch between Chinese and global cohorts would likely compress the stock sharply because the current enterprise value already capitalizes meaningful pipeline optionality.

The more consequential competitive read-through is for Zai Lab (ZLAB), whose ZL-1310 is also targeting DLL3 and may become the cleaner public comparable. IDE849 need not be best-in-class to create value, but it must show enough efficacy at tolerable doses to retain strategic value for a larger oncology buyer; this is particularly important given Hengrui’s role in early development and the uncertainty around ex-China reproducibility. In uveal melanoma, darovasertib must ultimately establish a credible role relative to Immunocore’s KIMMTRAK (IMCR), rather than merely produce response data in selected populations.

Consensus appears to underweight correlation risk: two positive datasets could increase confidence in platform execution, but they do not remove the financing and commercialization gap between early clinical proof-of-concept and registrational value. Over the next 6-18 months, the stock’s ceiling depends on moving IDE849 into a globally credible development path and defining a differentiated darovasertib label; otherwise, positive updates may become sell-the-news events. Thesis is falsified positively by durable survival data with manageable grade 3+ adverse events and a clear global dose/expansion plan; negatively by short response duration, material treatment discontinuations, or guidance implying extended cash needs before registrational studies.

Key Decisions for Investors

• Maintain IDYA as a watch-list event name rather than chase a directional position before the next IDE849 dataset; initiate only if implied move is below the stock’s realized post-data volatility and confirm cash runway extends through the next major global readout.
• For a tactical long, use a small IDYA position entered after efficacy and safety tables are released, not on headline language; target a 25-40% upside on differentiated durability, with a hard exit on evidence of dose-limiting toxicity, discontinuation rates above peer norms, or no global-development clarity.
• Monitor a relative-value pair: long IDYA / short ZLAB only if IDE849 shows materially superior duration or tolerability versus ZL-1310 at comparable exposure. Without cross-trial dose, safety, and follow-up data, this is an alert rather than an executable trade.
• Use IMCR as the key read-through hedge for darovasertib enthusiasm: avoid assigning strategic value to IDYA’s uveal melanoma program until data demonstrate a clinically meaningful advantage, complementary sequencing strategy, or addressable population beyond KIMMTRAK’s established position.